前收市價 | 0.7000 |
開市 | 0.7000 |
買盤 | 0.0000 |
賣出價 | 0.5000 |
拍板 | 95.00 |
到期日 | 2024-12-20 |
今日波幅 | 0.7000 - 0.7000 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 204 |
Apellis (APLS) declines as CHMP issues a second negative opinion for the approval of intravitreal pegcetacoplan to treat GA in the EU. The company plans to seek re-examination of the same.
Apellis (APLS) rises 3.3% as the treatment of GA patients with Syfovre demonstrates a visual function benefit in a prespecified endpoint at month 36 in a late-stage, long-term extension study.
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.